12,200 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, Holdings Channel reports. The institutional investor bought 12,200 shares of the company’s stock, valued at approximately $653,000.

A number of other hedge funds also recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its position in Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $139,000. Meeder Asset Management Inc. bought a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $159,000. Chicago Capital LLC bought a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $230,000. Finally, Cerity Partners LLC bought a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $239,000. Institutional investors own 75.39% of the company’s stock.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the transaction, the insider now directly owns 82,139 shares of the company’s stock, valued at $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the stock in a transaction dated Friday, March 7th. The shares were acquired at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares of the company’s stock, valued at approximately $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 10,002 shares of company stock valued at $348,203 over the last ninety days. 29.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on JANX. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Scotiabank reduced their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Buy” and an average target price of $95.25.

Janux Therapeutics Trading Up 3.8 %

NASDAQ JANX opened at $32.23 on Tuesday. Janux Therapeutics, Inc. has a 12 month low of $22.52 and a 12 month high of $71.71. The stock has a market cap of $1.90 billion, a P/E ratio of -27.55 and a beta of 3.27. The stock’s fifty day moving average price is $29.97 and its 200-day moving average price is $42.96.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.